Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327288 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
A Phase 1 study, sponsored by AmpliMed Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00327288 is a Phase 1 study that has completed, run by AmpliMed Corporation. The registered enrollment target is 34 participants.
The verdict
NCT00327288, a Phase 1 study, has completed, sponsored by AmpliMed Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imexon is administered on days 1-5 and the docetaxel on day 1 of every 3 week cycle. The objective of the protocol is to determine the highest dose of imexon which can be given with a full dose of docetaxel, and to provide information to enable the design of a future study focused on one or more specific cancer types.
Interventions
- DRUG docetaxel
- DRUG imexon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327288
The ClinicalTrials.gov registry entry for NCT00327288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AmpliMed Corporation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00327288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327288 about?
NCT00327288 is a clinical study titled "Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients". Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer. Docetaxel is approved by the Food and Drug Administration (FDA) as a second line therapy for these cancers. The imex...
What is the current status of trial NCT00327288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2005-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00327288?
The interventions under investigation include: docetaxel (DRUG), imexon (DRUG).
Who is sponsoring clinical trial NCT00327288?
This trial is sponsored by AmpliMed Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.